Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
about
Molecular Aspects of Head and Neck Cancer TherapyOptical metabolic imaging of treatment response in human head and neck squamous cell carcinomaHistones: Controlling Tumor Signaling CircuitryOral epithelial stem cells - implications in normal development and cancer metastasis.Cancer Epigenetics: Mechanisms and Crosstalk of a HDAC Inhibitor, VorinostatA comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of AktmTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma.Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR SignalingRole of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectivesVorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model.PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.Synthesis and characterization of a novel prostate cancer-targeted phosphatidylinositol-3-kinase inhibitor prodrug.Profile of panobinostat and its potential for treatment in solid tumors: an update.PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer.Human papillomavirus-associated adenocarcinoma of the base of tongue: potentially actionable genetic changes.Role of anoctamins in cancer and apoptosis.Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeletonDual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration.Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.Focal overexpression of CEACAM6 contributes to enhanced tumourigenesis in head and neck cancer via suppression of apoptosis.Biologic therapy in head and neck cancer: a road with hurdles.The anti-tumor effects of dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A on inducing autophagy in esophageal squamous cell carcinoma.Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines.[The epigenome. Target for innovative therapies in head and neck carcinoma].
P2860
Q28082815-E2F2DF90-6E89-4C57-957E-B25E894800AAQ28540413-4C5B15BE-027F-4766-8499-DD652782567AQ34109472-0E9137A6-A2E9-441D-AC28-E1F09306A1F8Q34147649-277B82C1-2F9A-4EF3-B450-2C65E6E8A0D8Q34213967-53C52505-B7A1-43D6-81C1-1E0EE6F8C804Q34458117-8A401CCA-F2F3-4138-9705-C09F45681427Q34852154-4728DA47-90E1-4B9F-BD64-E708A395AEB1Q35053837-59D344EC-90A7-4A35-9FE2-4C563B52D0CCQ35068192-AD555ABB-10CD-4042-B7F4-0DFB86068028Q35749913-154219B4-0DFB-419B-AF49-794936BF5D10Q36386428-C64522E1-75AA-45CD-B952-53F44BC0E3F4Q36501207-428DC6E1-C0E0-4DF0-B651-8C3D50318E31Q37025086-7541C351-C756-4B7C-8E54-D881FF76298AQ37082028-F32DC151-92FB-4B9E-9BF1-6FAFD46E071BQ37324186-1855BA40-A1A9-4C0A-9AB8-570614A9C28FQ37707021-0ABC77C4-6742-493E-A58A-9A0483571413Q38164587-D7326E2E-54B6-4C4B-A1A7-A0AF694913E6Q38184980-B571507D-F5CE-464B-867F-E60759C5334FQ38478630-6CE3AA96-67C9-45B3-8994-FAF2941BCAB6Q38819975-B633D9EB-239D-4271-A645-ECA773220A7EQ39214195-2D33526F-EF6C-4FE7-9313-242BE738F0A6Q39269702-CC78158B-94F6-4F03-B76F-D8DDE5751CF8Q42213295-50771E4B-A961-4C2A-BC69-A9252AAE015AQ52629243-3D1C9C14-F82F-4D37-B672-6A21931C2049Q52911914-466EA032-D500-411D-AF5C-9133F5E200F7Q53473691-DCB6CAD1-82CE-4ED8-89C4-7BD272761D20
P2860
Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Preclinical evaluation of dual ...... d neck squamous cell carcinoma
@ast
Preclinical evaluation of dual ...... d neck squamous cell carcinoma
@en
Preclinical evaluation of dual ...... d neck squamous cell carcinoma
@nl
type
label
Preclinical evaluation of dual ...... d neck squamous cell carcinoma
@ast
Preclinical evaluation of dual ...... d neck squamous cell carcinoma
@en
Preclinical evaluation of dual ...... d neck squamous cell carcinoma
@nl
prefLabel
Preclinical evaluation of dual ...... d neck squamous cell carcinoma
@ast
Preclinical evaluation of dual ...... d neck squamous cell carcinoma
@en
Preclinical evaluation of dual ...... d neck squamous cell carcinoma
@nl
P2093
P2860
P356
P1476
Preclinical evaluation of dual ...... d neck squamous cell carcinoma
@en
P2093
A Guminski
D Rickwood
L M de Long
M Hazar-Rethinam
R B Erlich
Z Kherrouche
P2860
P2888
P304
P356
10.1038/BJC.2011.495
P407
P577
2011-11-24T00:00:00Z
P5875
P6179
1036660720